Similarly, in another phase II multicenter clinical trial, lapatinib, a dual tyrosine kinase inhibitor targeting EGFR and ERBB2, was investigated in patients with castration-sensitive recurrent or metastatic PCa. This evidence concerns the gene ERBB2 and posterior cortical atrophy.